Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Hepatology International|February 8, 2023
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patientsXu Yang, Bowen Chen, Yanyu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Bi, Shanzhi Gu, et al.
Trials|November 11, 2014
Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trialJianhui Qu, Zujiang Yu, Qin Li, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialShukui Qin, Qiu Li, Shanzhi Gu, et al.
European Journal of Medical Research|October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 studyFeng Bi, Shukui Qin, Shanzhi Gu, et al.
Cancer Cell|May 28, 2019
Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular SubtypesRuidong Xue, Lu Chen, Chong Zhang, et al.
Journal of Cancer Research and Therapeutics|July 16, 2021
Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancerYingtian Wei, Yueyong Xiao, Zhongmin Wang, et al.
The Lancet. Oncology|June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 studyZhenggang Ren, Jianming Xu, Yuxian Bai, et al.
Hepatology International|November 21, 2024
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024George Lau, Shuntaro Obi, Jian Zhou, et al.
Liver Cancer|August 11, 2022
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert StatementsYongkun Sun, Wen Zhang, Xinyu Bi, et al.
Pageof 12